SK Biopharm Enters Joint R&D Partnership with Insilico Medicine for AI-Driven CNS Drug Discovery - Up to KRW 3.9 Trillion Contingent Agreement
SK Biopharm entered into a joint research agreement with Insilico Medicine to discover novel drug candidates in the CNS neuroimmune area using AI platform technology.
The contract value is up to KRW 3.95 trillion, consisting of an upfront payment of KRW 6.9 billion, milestone payments up to KRW 3.94 trillion, and royalties on net sales, with all payments contingent on achievement of agreed conditions.
There is no direct share dilution from this agreement, but significant milestone payments could strain finances if achieved.
[AI Summary]SK Biopharm secured a large contingent partnership to expand its CNS pipeline, with limited near-term stock impact but positive long-term growth potential. However, milestone uncertainty and financial burden are investment risks.
KOSPI Filing Information
Major Management Matters Related to Investment Decision (Execution of Joint Research and Development Partnership Agreement with Insilico Medicine)